# Unleashing anti-tumor immunity: Targeting the autophagy-related protein VPS34 to enhance STING agonist-based therapy

**Authors:** Elisabetta Bartolini, Kris Van Moer, Bassam Janji

PMC · DOI: 10.1080/27694127.2024.2370728 · Autophagy Reports · 2024-07-18

## TL;DR

This study shows that inhibiting VPS34 boosts the immune response in tumors by increasing chemokine production, improving the effectiveness of STING-based cancer therapies.

## Contribution

The study reveals a novel mechanism where VPS34 inhibition enhances STING agonist efficacy through cGAS-STING-dependent chemokine expression.

## Key findings

- VPS34 inhibition increases CCL5 and CXCL10 expression via a cGAS-STING-dependent mechanism in cancer cells.
- Pharmacological and genetic targeting of VPS34 enhances chemokine secretion across various tumor cell types.
- Combining VPS34 inhibition with STING agonist ADU-S100 improves outcomes in melanoma tumor-bearing mice.

## Abstract

The release of CCL5 and CXCL10 is essential for recruiting cytotoxic immune cells into the tumor microenvironment and enhancing the efficacy of cancer immunotherapy. Type I IFNs, particularly IFNβ, activate signaling pathways that induce the expression of these chemokines. In our recent study, we explored the impact and underlying mechanisms of inhibiting the kinase activity of VPS34, a key lipid kinase in the autophagy/endosomal trafficking system, on the expression of CCL5 and CXCL10 in preclinical cancer mouse models. Using NanoString gene expression technology, we analyzed tumors from mice treated with the VPS34 inhibitor SB02024 and demonstrated that the expression of CCL5 and CXCL10 is increased through a cGAS-STING-dependent mechanism within cancer cells. In vitro, both pharmacological inhibition and genetic targeting of VPS34 enhance cGAS-STING-mediated expression and secretion of CCL5 and CXCL10 across various tumor cell types. In vivo, treatment with the VPS34 inhibitor SB02024 enhances the positive effects of the STING agonist ADU-S100 in melanoma tumor-bearing mice. Thus, our study suggests that VPS34 inhibitors could be used to enhance STING-based anticancer therapies.

CCL5 (C-C motif chemokine 5); CXCL10 (C-X-C motif chemokine 10); IFN (interferon); VPS34 (vacuolar protein sorting 34); cGAS (cyclic GMP-AMP Synthase); STING (stimulator of interferon genes protein); cGAMP (2′3′-cyclic guanosine monophosphate–adenosine monophosphate).

## Linked entities

- **Genes:** CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352], CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627], PIK3C3 (phosphatidylinositol 3-kinase catalytic subunit type 3) [NCBI Gene 5289], CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004], STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061]
- **Proteins:** IFNB1 (interferon beta 1), CCL5 (C-C motif chemokine ligand 5), CXCL10 (C-X-C motif chemokine ligand 10), PIK3C3 (phosphatidylinositol 3-kinase catalytic subunit type 3), CGAS (cyclic GMP-AMP synthase), STING1 (stimulator of interferon response cGAMP interactor 1)
- **Chemicals:** SB02024 (PubChem CID 130359921), ADU-S100 (PubChem CID 123131802)
- **Diseases:** melanoma (MONDO:0005105)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tbk1 (TANK-binding kinase 1) [NCBI Gene 56480] {aka 1200008B05Rik}, NCR1 (natural cytotoxicity triggering receptor 1) [NCBI Gene 9437] {aka CD335, LY94, NK-p46, NKP46}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Cgas (cyclic GMP-AMP synthase) [NCBI Gene 214763] {aka E330016A19Rik, Mb21d1}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, Ifnb1 (interferon beta 1, fibroblast) [NCBI Gene 15977] {aka IFN-beta, IFNB, If1da1, Ifb}, CD8B (CD8 subunit beta) [NCBI Gene 926] {aka CD8B1, CD8beta, LEU2, LY3, LYT3, Ly-3}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, Becn1 (beclin 1, autophagy related) [NCBI Gene 56208] {aka Atg6}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, Pik3c3 (phosphatidylinositol 3-kinase catalytic subunit type 3) [NCBI Gene 225326] {aka 5330434F23Rik, Vps34}, Sqstm1 (sequestosome 1) [NCBI Gene 18412] {aka A170, OSF-6, Osi, STAP, STONE14, p62}, Ccl5 (C-C motif chemokine ligand 5) [NCBI Gene 20304] {aka MuRantes, RANTES, SISd, Scya5, TCP228}, NCR3 (natural cytotoxicity triggering receptor 3) [NCBI Gene 259197] {aka 1C7, CD337, LY117, MALS, NKp30}, Irf3 (interferon regulatory factor 3) [NCBI Gene 54131] {aka C920001K05Rik, IRF-3}
- **Diseases:** tumorigenesis (MESH:D063646), renal cell carcinoma (MESH:D002292), inflammatory (MESH:D007249), melanoma (MESH:D008545), Tumor (MESH:D009369)
- **Chemicals:** ADU-S100 (MESH:C000723773), 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (-), ATP (MESH:D000255), GTP (MESH:D006160), DMXAA (MESH:C066668)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** B16-F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11864653/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11864653/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11864653/full.md

---
Source: https://tomesphere.com/paper/PMC11864653